How Do Physical Capacity, Fatigue and Performance Differ in Children with Duchenne Muscular Dystrophy Compared with Their Healthy Peers?

Overview

Journal Neurosciences (Riyadh)

Specialty Neurology

Date 2018 Feb 19

PMID 29455220

Citations 2

Authors

Akmer Mutlu

Halil Alkan

Tuzun Firat

Aynur A Karaduman

Oznur T Yilmaz

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the fatigue levels and energy expenditure of children with Duchenne Muscular Dystrophy (DMD) at different functional levels with healthy children.

Methods: The cross-sectional study was carried out in the Unit of Pediatric Neuromuscular Diseases in the Department of Physiotherapy and Rehabilitation, Faculty of Health Science, Hacettepe University between March 2015 and January 2016. Fifty two children diagnosed with DMD in Level I-III according to the Brooke Functional Classification Scale and 17 healthy children were included in the study. The Six Minute Walk Test (6MWT), Northstar Ambulatory Assessment Scale (NSAA), Physiological Cost Index (PCI), and Timed performance tests were used to assess the children.

Results: Comparison in terms of PCI indicated a difference between Levels 2 and 3, and Levels 1 and 3 (p<0.0083). A difference was found in ascending and descending 4 stairs after 6MWT when fatigue after activity was evaluated.

Conclusion: The walking distances, fatigue levels and energy expenditure of DMD patients were higher than the healthy peers. This difference was more prominent with decreasing functional level.

Citing Articles

User Perspectives and Psychophysiological Manifestations of Fatigue with Trunk Orthosis for Dystrophinopathy Patients.

Rao A, Mujib M, Hasan M, Alokaily A, Tahira T, Qazi S Bioengineering (Basel). 2024; 11(8).

PMID: 39199738 PMC: 11351144. DOI: 10.3390/bioengineering11080780.

A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs.

Uchimura T, Asano T, Nakata T, Hotta A, Sakurai H Cell Rep Med. 2021; 2(6):100298.

PMID: 34195678 PMC: 8233665. DOI: 10.1016/j.xcrm.2021.100298.

References

Kalkman J, Schillings M, van der Werf S, Padberg G, Zwarts M, van Engelen B . Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005; 76(10):1406-9. PMC: 1739364. DOI: 10.1136/jnnp.2004.050005. View

Belanger A, Noel G, Cote C . A comparison of contractile properties in the preferred and nonpreferred leg in a mixed sample of dystrophic patients. Am J Phys Med Rehabil. 1991; 70(4):201-5. View

Kohler M, Clarenbach C, Bahler C, Brack T, Russi E, Bloch K . Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2008; 80(3):320-5. DOI: 10.1136/jnnp.2007.141721. View

Mazzone E, Martinelli D, Berardinelli A, Messina S, DAmico A, Vasco G . North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010; 20(11):712-6. DOI: 10.1016/j.nmd.2010.06.014. View

Boyd R, Fatone S, Rodda J, Olesch C, Starr R, Cullis E . High- or low- technology measurements of energy expenditure in clinical gait analysis?. Dev Med Child Neurol. 1999; 41(10):676-82. DOI: 10.1017/s0012162299001395. View

MacLaren D, Gibson H, Parry-Billings M, EDWARDS R . A review of metabolic and physiological factors in fatigue. Exerc Sport Sci Rev. 1989; 17:29-66. View

Keefer D, Tseh W, Caputo J, Apperson K, McGreal S, Morgan D . Comparison of direct and indirect measures of walking energy expenditure in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2004; 46(5):320-4. DOI: 10.1017/s0012162204000520. View

Miller R . Role of fatigue in limiting physical activities in humans with neuromuscular diseases. Am J Phys Med Rehabil. 2002; 81(11 Suppl):S99-107. DOI: 10.1097/00002060-200211001-00011. View

Feasson L, Camdessanche J, El Mandhi L, Calmels P, Millet G . Fatigue and neuromuscular diseases. Ann Readapt Med Phys. 2006; 49(6):289-300, 375-84. DOI: 10.1016/j.annrmp.2006.04.015. View

10.

McDonald C, Henricson E, Abresch R, Florence J, Eagle M, Gappmaier E . The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013; 48(3):343-56. PMC: 3824082. DOI: 10.1002/mus.23902. View

11.

McDonald C, Abresch R, Carter G, FOWLER Jr W, Johnson E, Kilmer D . Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil. 1995; 74(5 Suppl):S70-92. DOI: 10.1097/00002060-199509001-00003. View

12.

IJzerman M, Nene A . Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Arch Phys Med Rehabil. 2002; 83(12):1777-82. DOI: 10.1053/apmr.2002.35655. View

13.

Aboussouan L . Mechanisms of exercise limitation and pulmonary rehabilitation for patients with neuromuscular disease. Chron Respir Dis. 2009; 6(4):231-49. DOI: 10.1177/1479972309345927. View

14.

Martini J, Hukuda M, Caromano F, Favero F, Fu C, Voos M . The clinical relevance of timed motor performance in children with Duchenne muscular dystrophy. Physiother Theory Pract. 2014; 31(3):173-81. DOI: 10.3109/09593985.2014.989294. View

15.

Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2009; 9(1):77-93. DOI: 10.1016/S1474-4422(09)70271-6. View

16.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

17.

Lachmann R, Schoser B . The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?. Orphanet J Rare Dis. 2013; 8:160. PMC: 4015278. DOI: 10.1186/1750-1172-8-160. View

18.

Mazzone E, Messina S, Vasco G, Main M, Eagle M, DAmico A . Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord. 2009; 19(7):458-61. DOI: 10.1016/j.nmd.2009.06.368. View

19.

Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P . Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001; 56(3):336-40. DOI: 10.1212/wnl.56.3.336. View

20.

VIGNOS Jr P, SPENCER Jr G, ARCHIBALD K . Management of progressive muscular dystrophy in childhood. JAMA. 1963; 184:89-96. DOI: 10.1001/jama.1963.03700150043007. View